Related by context. All words. (Click for frequent words.) 74 Aflibercept 73 RhuDex 73 Daclizumab 73 ocrelizumab 72 investigational humanized monoclonal antibody 72 Golimumab 72 Panzem R 72 Romiplostim 72 baminercept 72 Phase 2b Clinical Trial 72 Febuxostat 72 Vandetanib 71 INCB# [001] 71 antibody MAb 71 Archexin 71 Nuvion 71 Meets Primary Endpoint 71 Epratuzumab 71 STRIDE PD 71 Dapagliflozin 71 ACTEMRA TM 71 MAGE A3 ASCI 71 Vicriviroc 71 Hsp# Inhibitor 71 RhuDex R 71 LymphoStat B belimumab 71 Glufosfamide 71 Pirfenidone 71 Factor VIIa 70 Pertuzumab 70 Tezampanel 70 Phase III Clinical Trial 70 teriflunomide 70 Iloperidone 70 oral prodrug 70 Denufosol 70 INSPIRE Trial Phase III 70 beta 1a 70 elotuzumab 70 Oral Fingolimod 70 Adalimumab 70 selective modulator 70 adalimumab Humira 70 phase IIb trial 70 Phase 2a Clinical Trial 70 Ofatumumab 70 mTOR mammalian target 70 PF # [002] 70 Tanespimycin 70 pertuzumab 70 Vitaxin 70 Phase 2b Trial 70 Plicera 70 Phase IIb Clinical Trial 70 Personalized Immunotherapy 70 Safinamide 69 Regeneron Pharma 69 GW# [003] 69 PDE4 inhibitor 69 Carfilzomib 69 antibody MT# 69 Vidofludimus 69 Completes Patient Enrollment 69 CTAP# Capsules 69 YONDELIS 69 novel VDA molecule 69 TNF Tumor Necrosis Factor 69 R lenalidomide 69 Prestara 69 Mipomersen 69 TBC# 69 Granulocyte Colony Stimulating Factor 69 Alemtuzumab 69 Androxal TM 69 Dasatinib 69 mertansine 69 Eculizumab 69 CIMZIA TM certolizumab pegol 69 midstage clinical 69 PEGylated Fab fragment 69 Temsirolimus 69 refractory chronic lymphocytic 69 Talabostat 69 CYT# potent vascular disrupting 69 cetuximab Erbitux R 69 BRAF inhibitor 69 MKC# MKC# PP 69 Teriflunomide 69 Tesmilifene 69 Hormone Refractory Prostate Cancer 69 Pivotal Phase III 69 HuMax EGFr 69 IL# PE#QQR 69 Enzastaurin 69 RhuDex TM 69 daclizumab 69 lumiliximab 68 Auxilium Pharma 68 Study Evaluating 68 Phase Ib study 68 Pivotal Study 68 Amrubicin 68 JAK2 Inhibitor 68 ATL# [001] 68 Phase 1b clinical trials 68 Azacitidine 68 Sapacitabine 68 Bosutinib 68 Oral NKTR 68 Achieves Primary Endpoint 68 KRN# 68 orally administered inhibitor 68 Phase 2a Trial 68 sorafenib tablets 68 PSMA ADC 68 evaluating Actimmune 68 Romidepsin 68 Drug Candidate 68 5 HT6 receptor 68 LymphoStat B TM 68 cathepsin K inhibitor 68 Multiple Ascending Dose 68 dasatinib Sprycel ® 68 Long Term Efficacy 68 ORENCIA R 68 tafamidis 68 NV1FGF 68 Phase Ib Clinical Trial 68 SNT-MC#/idebenone 68 cannabinor 68 evaluating tivozanib 68 brivaracetam 68 CHAMPION PCI 68 compound INCB# 68 First Patient Enrolled 68 Tasimelteon 68 registrational trial 68 seliciclib CYC# 68 riociguat 68 Phase III Trial 68 Preclinical Study 68 vidofludimus 68 alvespimycin 68 PEGylated anti 68 pan HDAC inhibitor 68 Phase IIa trial 68 GSK# [002] 68 HGS ETR2 68 HuLuc# 68 Phase IIb Trial 68 Rasagiline 68 Traficet EN 68 diarrhea predominant irritable 68 Aliskiren 68 Lubiprostone 68 Interferon Beta 68 Roche Actemra 68 AAG geldanamycin analog 68 Ambrisentan 68 PD LID 68 chronic eosinophilic leukemia 68 II Clinical Trial 68 SinuNase TM 68 interferon gamma 1b 68 Peginterferon alfa 2b 68 Cloretazine 68 SinuNase ™ 68 Severe Sepsis 68 MKC# MT 68 Initiate Phase 68 oral ridaforolimus 68 Nexavar sorafenib 68 Degarelix 67 Ixempra 67 telomerase therapeutic 67 Otelixizumab 67 First Patient Dosed 67 Certolizumab pegol 67 Pazopanib 67 mGluR2 NAM 67 Candesartan 67 Pimavanserin 67 Zorbtive TM 67 CIMZIA ™ 67 JAK inhibitor 67 PEGylated interferon beta 1a 67 Recombinant Human 67 R roscovitine 67 Belimumab 67 Prolongs Survival 67 Cimzia TM 67 CIMZIA TM 67 IgG1 monoclonal antibody 67 myelodysplastic myeloproliferative diseases 67 atacicept 67 Muraglitazar 67 multi kinase inhibitor 67 sunitinib Sutent 67 Velcade bortezomib 67 Phase IIb trials 67 Patients Treated With 67 humanized interleukin 6 67 Clinical Trial Results 67 Fludara ® 67 TRO# 67 Patient Enrollment 67 ELACYT 67 K ras mutations 67 tocilizumab 67 Campath alemtuzumab 67 PROMACTA 67 Adjuvant Treatment 67 Zarnestra 67 Pivotal Phase 67 IMA# 67 rasagiline tablets 67 Arimoclomol 67 Boceprevir 67 Phase Ib IIa 67 Elagolix 67 GAMMAGARD 67 AVASTIN 67 protein tyrosine phosphatase 1B 67 SPRYCEL ® 67 Initiates Clinical 67 Interferon beta 1a 67 Interferon beta 67 Lu AA# 67 Exelixis XL# 67 RhuDex ® 67 Telik Announces 67 PEG SN# 67 FOLOTYN ® 67 Initiates Enrollment 67 NDA Submission 67 IMC A# 67 Neuvenge 67 TACI Ig 67 Omacetaxine 67 panitumumab Vectibix 67 Xelox 67 Uvidem 67 IMC #B 67 Afatinib 67 SUTENT ® 67 sodium glucose cotransporter 67 sitaxsentan 67 alemtuzumab Campath 67 TYKERB 67 ANTEGREN 67 Natalizumab 67 Dose Escalation 67 xanthine oxidase inhibitor 67 tubulin inhibitor 67 Bortezomib 67 IRX 2 67 histone deacetylase HDAC inhibitor 67 Corlux 67 Phase 1b Clinical Trial 67 Remission Maintenance 67 enzastaurin 67 cMET 67 biologic therapy 67 chronic thromboembolic pulmonary 67 ENMD # 67 Laquinimod 67 MGd 67 CDP# 67 Decitabine 67 Systemic Sclerosis 67 RoACTEMRA 67 Synta Announces 67 Anti Tumor Activity 67 huC# DM4 67 Xanafide 67 CD# monoclonal antibody 67 Enzyme Replacement Therapy 67 HuMax CD# 67 Telcyta 67 receptor tyrosine kinase inhibitor 67 CD# CEA 67 ATL/TV# 67 Thiarabine 67 Chemokine 67 TRX1 67 Vernakalant 67 Prospective Randomized 67 SNT MC# 67 midstage trials 67 Silodosin 67 GATTEX TM 67 phase IIa clinical 67 Novel Oral 67 evaluating mipomersen 67 mGluR2 positive 67 Phase III Pivotal 67 depsipeptide 67 opioid induced bowel dysfunction 67 clazosentan 67 myelofibrosis polycythemia vera 67 Zenvia Phase III 66 Phase Ib clinical trials 66 Investigational Treatment 66 PEG PAL 66 Phase Ib clinical 66 Blinatumomab 66 Trastuzumab DM1 66 neratinib 66 HDAC Inhibitor 66 Rebif ® 66 cinacalcet HCl 66 6R BH4 66 proteasome inhibitor 66 Zenvia ™ 66 Phase III Clinical Trials 66 eprotirome 66 Pegloticase 66 Oxypurinol 66 Granted Orphan Drug 66 Tolvaptan 66 Antitumor Activity 66 Bafetinib 66 ALN HPN 66 ULORIC 66 Dacogen injection 66 Zemplar Capsules 66 Forodesine HCl 66 Elocalcitol 66 PRT# 66 Bezielle 66 Serdolect ® 66 Panzem R NCD 66 Aplidin 66 Aurora Kinase 66 Dose Ranging Study 66 guanfacine extended release 66 mGluR5 negative 66 glufosfamide 66 Deforolimus 66 GRN# 66 sunitinib malate 66 Fibrillex TM 66 Symadex 66 PNP inhibitor 66 Randomized Phase 66 thalidomide Thalomid 66 SUCCEED trial 66 Combination REOLYSIN R 66 Epidermal Growth Factor Receptor 66 oral FTY# 66 non nucleoside inhibitor 66 XL# anticancer compounds 66 volociximab 66 phase IIb study 66 Sym# 66 Saxagliptin 66 Exherin TM 66 gefitinib Iressa 66 Proxinium TM 66 Onconase 66 omacetaxine mepesuccinate 66 CEQ# 66 HuMax CD4 66 Cimzia ® certolizumab pegol 66 GOUT 66 CYP#A# substrate 66 Virulizin ® 66 JAK1 66 FLT3 66 Elvitegravir 66 dextromethorphan quinidine 66 Brentuximab Vedotin SGN 66 Ceflatonin 66 Troxatyl 66 MyVax R 66 Raptiva ® 66 Randomized Double blind 66 systemic anaplastic large 66 SGLT2 66 HER2 positive metastatic breast 66 Pivotal Trial 66 Vidaza azacitidine 66 nilotinib Tasigna 66 HCV Protease Inhibitor 66 Initiates Clinical Trial 66 ICA # 66 HCD# [002] 66 R#/MEM 66 Initiate Clinical Trial 66 mu opioid receptor antagonist 66 Herceptin trastuzumab 66 Phase IIa Clinical Trial 66 Alvine Pharmaceuticals 66 cediranib 66 Monotherapy 66 Trastuzumab 66 Irinotecan 66 rilonacept 66 adenosine injection 66 class mGluR5 inhibitor 66 Aptivus ® 66 virus HCV protease inhibitor 66 Pharmacokinetics PK 66 fostamatinib 66 Biomarker Study 66 trastuzumab DM1 66 Ranolazine 66 Firazyr 66 Lenalidomide 66 Myelofibrosis 66 Investigational Compound 66 Psoriasis Drug 66 ZOLINZA 66 Annamycin 66 Certolizumab 66 Nexavar ® 66 Hedgehog Pathway Inhibitor 66 GRNCM1 66 By JENNIFER LEARN 66 Gleevec resistant 66 AEG# 66 angiogenesis inhibitor 66 BZL# 66 visilizumab 66 sargramostim 66 Campath ® 66 Telik logo TELINTRA 66 oral dual endothelin 66 JAK inhibitors 66 Etanercept 66 N acetylgalactosamine 6 66 hypereosinophilic syndrome 66 Anti Tumor 66 hyperphenylalaninemia HPA due 66 EndoTAG TM -1 66 Ozarelix 66 Saforis 66 Plaque Psoriasis 66 Pradefovir 66 thetreatment 66 hypoxia activated prodrug 66 selective inhibition 66 2A receptor agonist 66 Telbivudine 66 huN# DM1 66 fosbretabulin 66 FDA APPROVES 66 generation purine nucleoside 66 HQK 66 IAP inhibitor 66 mGluR5 NAM 66 MEK Inhibitor 66 Tesetaxel 66 octreotide implant 66 motesanib 66 JAK Inhibitor 66 Raptiva R 66 sorafenib Nexavar 66 phase IIa 66 KNS # 66 Cimzia certolizumab pegol 66 teplizumab 66 Mg Usa 66 ACZ# 66 vWF 66 Cyclooxygenase 2 66 ularitide 66 chronic idiopathic thrombocytopenic purpura 66 SYN# 66 octreotide acetate 66 BAL# [002] 66 Varespladib 66 SinuNase 66 BRIM2 66 PDE# inhibitors 66 Novolimus 66 phase IIIb 66 selective androgen receptor modulator 66 Betaferon R 66 recurrent glioblastoma multiforme 66 BRIM3 66 forodesine 66 Chronic Lymphocytic Leukemia CLL 66 Tumor Response 66 targeted radiotherapeutic 66 Akt activation 66 phase IIb clinical 66 Tumor Necrosis Factor 66 lintuzumab SGN 65 Vimpat R 65 Microplasmin 65 Immunotherapeutic 65 urocortin 2 65 entinostat 65 Ixabepilone 65 mapatumumab 65 Bucindolol 65 talabostat 65 Cardiotoxicity 65 #D#C# 65 Quinamed 65 rNAPc2 65 Successfully Completes Phase 65 mGluR2 65 Biogen Genentech 65 Cutaneous T 65 Simulect 65 develop HBV reactivation 65 Tocilizumab 65 phase III isavuconazole 65 INCB# [003] 65 pathophysiological effects 65 Triolex 65 R#/MEM # 65 Fc fusion protein 65 EVIZON TM 65 OXi# 65 LibiGel ® 65 Phenoptin 65 goserelin 65 prucalopride 65 Pivotal Clinical Trial 65 DDP# 65 GLPG# 65 vapreotide acetate 65 VitiGam 65 FDA Accepts 65 R sorafenib tablets 65 OMAPRO ™ 65 pralatrexate injection folate analogue 65 icatibant 65 Darusentan 65 atypical Hemolytic Uremic Syndrome 65 Cethromycin 65 hA# 65 SAR# [004] 65 Torisel 65 pharmacokinetic PK study 65 febuxostat 65 CAMPATH 65 Prostate AdenoCarcinoma Treatment 65 Seliciclib 65 TMC# [002] 65 kidney urologic 65 Clinical Trial Data 65 Aurora kinase 65 Xcytrin R 65 Maribavir 65 XmAb# 65 androgen receptor AR 65 somatostatin analog 65 Diamyd ® 65 Canvaxin 65 Cetrorelix 65 Nicotine Vaccine 65 TO AVOID PREGNANCY WHILE 65 peptibody 65 ATACAND 65 metastatic malignant 65 Ustekinumab 65 Liprotamase 65 arzoxifene 65 AVE# 65 BCX# 65 Preclinical Data 65 CYP#A# CYP#D# 65 methylnaltrexone bromide 65 trastuzumab Herceptin R 65 Luteinizing Hormone Releasing Hormone 65 phase Ib 65 TELCYTA 65 LymphoStat B 65 HCV RESPOND 2 65 Clofarabine 65 Bifeprunox 65 RAPTIVA 65 Vectibix panitumumab 65 developing Bicifadine serotonin 65 Therapeutic Vaccine 65 MyVax 65 humanized anti 65 Shows Efficacy 65 Catena ® 65 peripherally acting 65 Atacicept 65 DAVANAT 65 efalizumab 65 FASLODEX 65 Trabectedin 65 Bevacizumab 65 Phase Ib II 65 alvimopan 65 sunitinib Sutent ® 65 Improved Survival 65 bosutinib 65 Advanced Renal Cell 65 Phase #b/#a clinical 65 Actimmune ® 65 Bayer Nexavar 65 steroid refractory ulcerative 65 Trandolapril 65 IND Filing 65 reslizumab 65 PHX# 65 Kinase Inhibitor 65 ofatumumab HuMax CD# 65 Everolimus 65 Dalbavancin 65 rheumatoid arthritis psoriatic arthritis 65 LUX Lung 65 Revlimid lenalidomide 65 Humanized Anti 65 Ceflatonin R 65 TYZEKA 65 LAF# 65 dasatinib Sprycel 65 REVIVE Diabetes 65 Telintra 65 Demonstrates Positive 65 Aryplase 65 Milnacipran 65 PLK1 SNALP 65 QLT# 65 Cannabinor 65 GTC recombinant form 65 PDX pralatrexate 65 deforolimus 65 CCR9 antagonist 65 axitinib 65 Initiates Phase III 65 R Saizen R 65 Previously Treated 65 docetaxel Taxotere ® 65 Alequel 65 A3 adenosine receptor 65 Diabetic Neuropathy 65 Oral Calcitonin 65 Gleevec imatinib mesylate 65 aurora kinase 65 dacetuzumab 65 Aviptadil 65 Neurodex 65 Diamyd R 65 Pivotal Phase II 65 Lung Cancer Drug 65 Ridaforolimus 65 mTOR kinase 65 Alexion Pharma 65 Bicifadine 65 Alzhemed TM 65 targeting CD# 65 Vion Pharmaceuticals 65 formerly LymphoStat B 65 pradefovir 65 FOLFOX6 chemotherapy regimen 65 Genz # 65 mTOR inhibitor 65 LEVADEX TM 65 BAY #-# 65 pediatric Crohn disease 65 Voreloxin 65 recurrent metastatic ovarian cancer 65 OvaRex MAb 65 Receives Orphan Drug Designation 65 Atrasentan 65 preclinically 65 dimebon 65 Ticagrelor 65 Panzem 65 oncolytic virus therapies 65 Tarceva TM 65 HCV SPRINT 65 novel histone deacetylase 65 dimebon latrepirdine 65 DEB# 65 Allovectin 7 65 erlotinib Tarceva ® 65 CanAg 65 APTIVUS 65 azilsartan medoxomil 65 including eniluracil ADH 65 tiapamil 65 hematological parameters 65 unique alkylating agent 65 alefacept 65 RELOVAIR ™ 65 Efficacy Results 65 Randomized Phase II 65 albiglutide 65 LY# [002] 65 Bosentan 65 Clolar ® 65 ACTILON 65 #beta HSD1 65 dyskinesia PD LID 65 Phase IIb clinical trials 65 ProSavin 65 CCR5 receptor antagonist 65 Naive Patients 65 T#I [002] 65 Adentri 65 Tarvacin 65 Pulmonary Arterial Hypertension 65 peptidic compound 65 nalbuphine ER 65 Elesclomol 65 Keryx Biopharma 65 Exelixis compounds 65 severe gastroparesis 65 orally bioavailable 65 trial evaluating PRX# 65 TELINTRA 65 gastrointestinal stromal tumors GIST 65 NP2 Enkephalin 65 ospemifene 65 zanolimumab 65 R# #mg BID 65 Fabry Disease 65 AMEVIVE 65 VAPRISOL 65 Alfimeprase 65 Dupuytren Contracture 65 bardoxolone 64 Interferon beta 1b 64 investigational immunotherapy 64 Lupus Nephritis 64 Desmoteplase 64 Hedgehog antagonist 64 bortezomib Velcade 64 severe hypercholesterolemia 64 Clavis Pharma 64 pharmacodynamic profiles 64 allosteric modulator PAM 64 FDA Approvable Letter 64 Nanobody 64 GALNS 64 metastatic colorectal 64 Reverset 64 Files IND 64 Rigel R# 64 metastatic castration resistant 64 CCX# B 64 senicapoc 64 Fulvestrant 64 Copegus ® 64 novel synthetic PEGylated 64 radiation sensitizer 64 Anticalin R 64 eprodisate Fibrillex TM 64 GLP toxicology studies 64 AZILECT R 64 CRMD# 64 Trial Evaluating 64 ThermoDox ® clinical 64 ruxolitinib 64 Janus kinase 64 drug figitumumab 64 AGILECT R 64 NPC 1C 64 PXD# 64 ZEVALIN ® 64 refractory metastatic 64 BLP# Liposome Vaccine 64 depressive episodes associated 64 Valdoxan 64 CCR9 64 Rasilez Tekturna 64 galiximab 64 acyclovir Lauriad R 64 REMINYL ® 64 Disease Progression 64 pharmacodynamic effects 64 Phase #b/#a trial 64 dirucotide 64 OncoVex 64 cancer neuroendocrine tumor 64 ToGA 64 PROSTVAC ® 64 reduce serum phosphate 64 Dementia Related Psychosis 64 GAMMAGARD LIQUID 64 Teplizumab 64 SILENOR 64 Presents Preclinical Data 64 trastuzumab DM1 T DM1 64 Tracleer R 64 IgG1 antibody 64 Fx #A 64 Rheumatoid Arthritis Drug 64 iniparib 64 memantine HCl 64 anakinra 64 figitumumab 64 PANVAC VF 64 FBPase 64 relapsing multiple sclerosis 64 Relapsed Refractory 64 Lenocta 64 schizophrenia CIAS 64 topoisomerase II inhibitor 64 Kuvan R 64 Phase IIB 64 Pralatrexate 64 Arranon 64 Sutent sunitinib 64 BCR ABL inhibitor 64 Azedra 64 etanercept Enbrel 64 Adenoma Prevention 64 MCSP respectively 64 Roflumilast 64 mucosal healing 64 oral picoplatin 64 LAB CGRP 64 Drug Shows Promise 64 midstage studies 64 Solid Tumors 64 liposomal formulation 64 allosteric modulator NAM 64 HGS# 64 Pemetrexed 64 Gamunex C 64 methylnaltrexone 64 Angiotensin Converting Enzyme 64 ThermoDox R 64 Cloretazine ® 64 EXPAREL TM 64 erlotinib Tarceva 64 HuMax TAC 64 aplindore 64 diabetic neuropathic pain 64 ZACTIMA 64 bosentan Tracleer 64 Capesaris 64 investigational pharmacologically unique 64 canakinumab 64 Tyrosine Kinase Inhibitor 64 candesartan cilexetil 64 Kepivance 64 Castration Resistant Prostate Cancer 64 non peptidic protease 64 Desvenlafaxine Succinate 64 generation antisense inhibitor 64 Eltrombopag 64 Rheumatoid Arthritis RA 64 abatacept Orencia 64 Plecanatide 64 follicular Non Hodgkin 64 glucagon receptor 64 Tofacitinib 64 CML CP 64 Panzem ® 64 Inhalation Solution 64 Onco TCS 64 alfa 2a 64 Femara letrozole 64 posaconazole 64 highly selective inhibitor 64 polymerase inhibitor 64 STELARA TM 64 EDARBI 64 cetuximab Erbitux 64 ONCONASE R 64 Chemophase 64 PKC# 64 REGN# 64 Promacta 64 ixabepilone 64 humanized therapeutic 64 Biogen Idec Elan 64 GENR 64 Infliximab 64 Acute Ischemic Stroke 64 terlipressin 64 Oral Formulation 64 Antigen Specific 64 Ataluren 64 Phase IIIb clinical 64 Rilonacept 64 PEGINTRON TM 64 Acute Heart Failure 64 safinamide 64 Tocosol Paclitaxel 64 Abatacept 64 MabCampath 64 Protease Inhibitor 64 CytoFabTM 64 hypoxia selective 64 cell lymphoma CTCL 64 ® lenalidomide 64 Adjunctive Therapy 64 mGlu2 3 64 Valopicitabine 64 bevacizumab Avastin ® 64 Tyrima 64 Glatiramer Acetate 64 acetonide FA 64 Investigational Oral 64 CCX# 64 ORENCIA ® 64 Methylnaltrexone 64 Chemokine Receptor 64 ISIS # 64 lintuzumab 64 EOquin TM phase 64 INS# [001] 64 ropinirole Requip 64 painful diabetic neuropathy 64 Omnitarg 64 Fingolimod 64 dirucotide MBP# 64 Rituximab 64 Dyloject TM 64 Initiates Phase II 64 Zoraxel 64 Tipranavir 64 pomalidomide 64 Onrigin 64 Cariprazine 64 Factor Receptor 64 JAK2 inhibitor 64 PI3K/mTOR 64 Phase III Trials 64 Initiated Phase 64 Tarvacin TM 64 AstraZeneca Iressa 64 ® bortezomib 64 Nilotinib 64 induced macular edema 64 PDUFA Date 64 Phase 2b Study 64 Genentech Rituxan 64 PSN# [002] 64 LY# [003] 64 Vaprisol 64 Pegintron 64 Certican 64 Panitumumab 64 Xinlay 64 BCG refractory carcinoma 64 Hematological Malignancies 64 tesmilifene 64 orally inhaled migraine 64 Alocrest 64 tramiprosate Alzhemed TM 64 nonclinical studies 64 PRIALT 64 NOXAFIL 64 Exemestane 64 ACADIA Pharmaceuticals 64 comparing alemtuzumab 64 Faropenem 64 BENLYSTA ® 64 elacytarabine 64 CB2 selective receptor agonist 64 metaglidasen 64 Antiviral Activity 64 Phase 2a trial 64 Phase 1a clinical 64 Æterna Zentaris 64 regorafenib 64 Sudhir Agrawal D.Phil 64 Xcellerated T Cells 64 eltrombopag 64 Demonstrates Potent 64 ADVEXIN p# therapy 64 triphendiol 64 otelixizumab 64 PHASE III 64 KIACTA ™ 64 HCV protease 64 Diabetic Nephropathy 64 2 methoxyestradiol 64 lorvotuzumab mertansine 64 Demonstrated Significant 64 Investigational Drug 64 Antisoma AS# 64 personalized cellular immunotherapy 64 Insegia 64 erlotinib Tarceva R 64 XYOTAX TM 64 Olaparib 64 human IgG1 monoclonal 64 Xeloda ® 64 Cinacalcet 64 MORAb 64 MYDICAR ® 64 AA Amyloidosis 64 Anticalin ® 64 Squalamine 64 oral ghrelin agonist 64 LEUKINE 64 preclinical efficacy 64 small molecule thrombopoietin 64 Liposomal 64 Pafuramidine 64 Myocet 64 YONDELIS R 64 familial amyloidotic polyneuropathy FAP